NovoCure’s Tumor Treating Fields Help Mesothelioma Patients Live Longer In STELLAR Trial
Executive Summary
New results from the Phase II STELLAR trial shows Tumor Treating Fields therapy in conjunction with chemotherapy extends survival in previously untreated mesothelioma patients with no safety problems.
You may also be interested in...
Higher Doses Of Novocure’s TTF Help New Glioblastoma Patients
The first reported analysis demonstrating a patient-level dose response with Novocure’s Tumor Treating Fields therapy is now published. The post-hoc analysis of the EF-14 trial showed higher doses of Tumor Treating Fields improved survival in newly diagnosed glioblastoma patients.
Novocure Launches INNOVATE 3 Trial Of Ovarian Cancer Therapy
INNOVATE 3 is a phase 3 pivotal trial testing the efficacy of Novocure's Tumor Treating Fields therapy combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.
Novocure Advances Tumor Treating Fields Technology For Patients With Newly Diagnosed Glioblastoma
Novocure’s tumor treating fields technology offers hope to the 10,000 to 12,000 patients in the US diagnosed with glioblastoma multiforme (GBM), the most common and deadliest form of malignant primary brain tumor. The EF-14 Phase III clinical trial evaluating the company’s Optune device for newly diagnosed GBM was terminated due to early success, and in December 2014, the FDA approved an IDE supplement allowing all control patients in the trial to receive the treatment.